Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference
January 04 2021 - 8:30AM
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced that its president and
chief executive officer, Steven Lo, will present a company overview
at the H.C. Wainwright Virtual BioConnect Conference that will be
available on Monday, January 11, 2021 at 6:00 am ET.
A webcast of the presentation can be accessed on
the company’s website at
http://ir.zosanopharma.com/events-presentations. The archived
webcast will remain available for 90 days following the date of the
event.
About Zosano PharmaZosano Pharma
Corporation is a clinical-stage biopharmaceutical company focused
on developing products where rapid administration of approved
molecules with established safety and efficacy profiles may provide
substantial benefit to patients, in markets where patients remain
underserved by existing therapies. The company’s transdermal
microneedle system technology consists of titanium microneedles
coated with drug that are designed to enable rapid systemic
administration of therapeutics to patients. Zosano’s lead product
candidate is Qtrypta™ (M207), which is a proprietary formulation of
zolmitriptan designed to be delivered via its transdermal
microneedle system technology, as an acute treatment for migraine.
Learn more at www.zosanopharma.com.
Zosano Contact:Christine
MatthewsChief Financial Officer 510-745-1200
PR Contacts:Sylvia Wheeler or
Alexandra Santosswheeler@wheelhouselsa.com or
asantos@wheelhouselsa.com
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Apr 2023 to Apr 2024